<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594216</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 02112</org_study_id>
    <nct_id>NCT01594216</nct_id>
  </id_info>
  <brief_title>Ruxolitinib in Estrogen Receptor Positive Breast Cancer</brief_title>
  <official_title>A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in&#xD;
      combination with Exemestane in patients with estrogen-receptor positive advanced breast&#xD;
      cancer. The objective of this study is to determine the preliminary safety and efficacy of&#xD;
      the combination of exemestane and Ruxolitinib (INCB018424).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 9, 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Estrogen-receptor Positive Invasive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>First Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <arm_group_label>First Stage</arm_group_label>
    <arm_group_label>Second Stage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>First Stage</arm_group_label>
    <arm_group_label>Second Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed, invasive metastatic breast cancer.&#xD;
&#xD;
          -  Estrogen-receptor positivity (defined by at least 5% staining by immunohistochemistry)&#xD;
             on either the primary breast tumor or a metastatic biopsy.&#xD;
&#xD;
          -  Postmenopausal status, defined as: either &quot;surgical menopause&quot; via oophorectomy, or&#xD;
             &quot;natural menopause&quot; in which the patient has had no menses in the previous 12-month&#xD;
             period. Premenopausal patients who have been been rendered amenorrheaic by tamoxifen&#xD;
             must have a serum estradiol level &lt;30 pg/ml after discontinuation of tamoxifen.&#xD;
             Amenorrheaic premenopausal subjects must have a negative pregnancy test during&#xD;
             screening (prior to enrollment) and must be advised to use adequate contraception&#xD;
             throughout their participation.&#xD;
&#xD;
          -  Prior therapy for the current malignancy: Patient must have 1) relapsed on or within 2&#xD;
             years of completing adjuvant hormonal therapy with a non-steroidal aromatase&#xD;
             inhibitor, OR 2) failed a non-steroidal aromatase inhibitor in the metastatic setting.&#xD;
             There is no limit to prior chemotherapy or hormonal regimens for this malignancy.&#xD;
&#xD;
          -  At least one measureable lesion by RECIST or mainly lytic bone lesions in the absence&#xD;
             of measurable disease. Bone-only disease is allowed.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ function, defined as follows:&#xD;
&#xD;
        Bilirubin ≤ 1.5 x the upper limit of normal (ULN) Serum creatinine ≤ 1.5 x UNL or&#xD;
        calculated creatinine clearance ≥ 60 mL/min, and&#xD;
&#xD;
          -  For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) ≤ 2.5 x ULN&#xD;
&#xD;
          -  For subjects with liver metastases: alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase ≤ 5 x ULN&#xD;
&#xD;
          -  Adequate bone marrow function, defined as follows Absolute neutrophil count (ANC)&#xD;
             &gt;1500/mm3 Hemoglobin &gt; 9 Platelets &gt;100,000/mm3&#xD;
&#xD;
          -  The subject is capable of understanding and complying with the protocol requirements&#xD;
             and has signed the informed consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Chemotherapy, hormonal therapy or investigational anti-tumor therapy within 21 days of&#xD;
             starting study treatment. Use of bone-building agents is allowed.&#xD;
&#xD;
          -  Prior treatment with exemestane.&#xD;
&#xD;
          -  Any type of investigational agent within 28 days before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Unresolved clinically-meaningful toxicity due to prior therapy. Toxicity from previous&#xD;
             treatment must be back to baseline or Grade ≤ 1, with the exception of neurotoxicity&#xD;
             and alopecia.&#xD;
&#xD;
          -  Untreated or uncontrolled brain metastases or evidence of leptomeningeal involvement&#xD;
             of disease. Patients who have stable disease after radiotherapy for CNS disease are&#xD;
             eligible. Testing for brain involvement in the absence of symptoms is not required as&#xD;
             part of this protocol.&#xD;
&#xD;
          -  Uncontrolled, intercurrent illness&#xD;
&#xD;
          -  Known ongoing or active infection, including active hepatitis B or hepatitis C.&#xD;
             Testing for hepatitis B or C is not required as part of this protocol.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial&#xD;
             infarction within 3 months&#xD;
&#xD;
          -  A baseline corrected QT interval (QTc) &gt; 470 ms.&#xD;
&#xD;
          -  The subject is known to be positive for the human immunodeficiency virus (HIV). Note:&#xD;
             baseline HIV screening is not required&#xD;
&#xD;
          -  The subject is unable or unwilling to abide by the study protocol or cooperate fully&#xD;
             with the investigator or designee.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela DiMichele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>10104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <disposition_first_submitted>April 29, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 5, 2020</disposition_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

